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Although protein ADP-ribosylation is involved in diverse biological processes, it has remained
a challenge to identify ADP-ribose acceptor sites. Here, we present an experimental workﬂow
for sensitive and unbiased analysis of endogenous ADP-ribosylation sites, capable of
detecting more than 900 modiﬁcation sites in mammalian cells and mouse liver. In cells,
we demonstrate that Lys residues, besides Glu, Asp and Arg residues, are the dominant
in vivo targets of ADP-ribosylation during oxidative stress. In normal liver tissue, we ﬁnd Arg
residues to be the predominant modiﬁcation site. The cellular distribution and biological
processes that involve ADP-ribosylated proteins are different in cultured cells and liver tissue,
in the latter of which the majority of sites were found to be in cytosolic and mitochondrial
protein networks primarily associated with metabolism. Collectively, we describe a robust
methodology for the assessment of the role of ADP-ribosylation and ADP-ribosyltransferases
in physiological and pathological states.
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P
rotein ADP-ribosylation refers to the process where an
ADP-ribose moiety is transferred from NADþ to the
amino acid side-chains of target proteins (as mono-ADP-
ribose, MAR) or to an already protein bound ADP-ribose to
form poly-ADP-ribose (PAR). These modiﬁcations are primarily
catalysed by a class of enzymes known as ADP-ribosyltransferases
(ARTs), with certain Sirtuin deacetylases also being able to
catalyse ADP-ribosylation1. The ARTs can be divided further
into two major subclasses: ARTCs (cholera toxin-like) and
ARTDs (diphtheria toxin-like, formerly called poly(ADP-ribose)
polymerases (PARPs)), depending on their conserved structural
features2.
While MARylation has been reported to modulate GSK3b
kinase activity and NF-kB signalling3, little is known about the
biological functions of this type of modiﬁcation. In contrast,
PARylation has emerged as a crucial post-translational
modiﬁcation (PTM) in cancer development4. PARylation is a
transient PTM5, whose rapid cellular degradation is
predominantly carried out by PAR glycohydrolase (PARG)6.
While PARylation is a key component of the DNA damage
response (DDR) via its central role in the base excision repair
pathway, many of the molecular details and processes affected by
ARTs remain poorly understood. As a result, a detailed
understanding of the molecular mechanisms and functions
affected by ADP-ribosylation remains elusive.
In particular, the inventory of the amino acid residues
modiﬁed by ADP-ribosylation remains incomplete. Current
experimental evidence suggests that ADP-ribosylation primarily
occurs on four different amino acids; Lys7, Arg8, Asp and
Glu residues9. In addition, Cys residues were reported to
be MARylated by certain ARTDs or bacterial toxins10.
High-resolution mass spectrometry (MS) has become a valuable
tool for comprehensive identiﬁcation of PTMs11. However,
current MS-based approaches for mapping ADP-ribosylation
sites are biased towards modiﬁcations of only Glu and Asp9,
or they lack sensitivity due to co-enrichment of other PTMs
(that is, phosphorylated peptides)12.
Moreover, protein ADP-ribosylation is a low-abundant
PTM that is rapidly degraded. To overcome this challenge
cellular PARG knockdowns (siPARG) or knockouts have been
developed9,12. Unfortunately, cellular absence of PARG leads
to physiological alterations in cells, hepatocellular carcinoma
in mice13, progressive neurodegeneration14 and excessive
accumulation of PAR chains that are not rapidly degraded and
promote cell death via parthanatos15. Consequently, strategies
requiring knockdown of PARG constitute an improper setting for
analysing physiological ADP-ribosylation and its associated
mechanisms, thus rendering these methods inapplicable for
in vivo analysis of tissues without genetic interventions16.
Moreover, while ADP-ribosylation has been known for more
than 50 years, the cellular stoichiometry of the modiﬁcation has
remained elusive, primarily due to the lack of methodologies that
can elucidate such information17.
Recently a chemical genetic discovery method for
ARTD targets was reported18, where the NADþ analogue
8-Bu(3-yne)T-NADþ was incubated with cell lysates from cells
overexpressing mutated ARTDs sensitive to the analogue or cell
lysates spiked with recombinant mutated ARTDs. However, as
NADþ is impermeable to the cell membrane, this method
requires either the lysis of cells or the isolation of organelles
(that is, nuclei) followed by the complementation of exogenous
8-Bu(3-yne)T-NADþ , which renders the identiﬁcation of
ARTD-speciﬁc substrates under different cellular conditions,
and at physiological NADþ levels unattainable. Moreover, the
ADP-ribose acceptor sites identiﬁed using this methodology were
limited to Glu and Asp modiﬁcations9.
To address these limitations, we have developed a protocol for
the unbiased mapping of endogenous ADP-ribosylation sites in
proteins. Our method led to the identiﬁcation of more than 500
endogenous ADP-ribosylation sites in a single analysis and, as a
result, provides an unprecedented in-depth analysis of protein
ADP-ribosylation. Importantly, as the described workﬂow is
applied under genetically unperturbed physiological conditions,
we have used our methodology to analyse ADP-ribosylation sites
in both cultured mammalian cells and mouse liver. Collectively,
the workﬂow presented here represents a major advance in the
detection of ADP-ribose acceptor sites and the identiﬁcation
of cellular processes regulated by ADP-ribosylation. Thus,
facilitating a better understanding of the complex physiological
and pathological processes that involve ADP-ribosylation,
and the treatment of such conditions with PARP (that is,
ADP-ribosylation) inhibitors.
Results
Identiﬁcation of endogenous ADP-ribosylation sites. We have
developed a technology for sensitive analysis of endogenous
ADP-ribosylation sites in both cells and tissues that overcomes
several of the above-mentioned limitations of current approaches.
Brieﬂy, proteins are isolated from cells, digested into peptides
ﬁrst using LysC and then trypsin. We then treat the cellular
peptide digest with PARG, thereby converting all PARylated
amino acids to their MARylated counterparts19. While this
prevents discriminating whether the modiﬁcation was originally
PARylation or MARylation, the conversion is crucial for feasible
MS analysis. Furthermore, this has the advantage that MARylated
peptides can be unbiasedly enriched with an ADP-ribose-speciﬁc
domain20. In contrast to previously described methodologies21,
enrichment at the peptide level with Af1521 in combination with
prior PARG treatment has not been performed before.
Subsequently, the enriched ADP-ribosylated peptides and their
acceptor sites are identiﬁed using a high-resolution Orbitrap mass
spectrometer (Q Exactive HF). As no pre-fractionation steps are
employed, the described workﬂow analyses ADP-ribosylated
peptides from a single sample requiring only a few hours
of sensitive LC-MS operation22. All peptides are fragmented
using higher-energy collisional dissociation (HCD) ensuring high
p.p.m. accuracy on both the precursor and fragment ions23.
Furthermore, ADP-ribosylated peptide identiﬁcation is aided
by diagnostic ions originating from the fragmentation of the
ADP-ribose group linked to the peptide24,25 (Supplementary
Fig. 1a). Superior advancements over current methodologies are
as follows: First, sample preparation without ARTD, NADþ or
PARG level perturbation9,18 allows analysis of both cells and
tissues under physiological conditions. This will allow us to
broaden our understanding of the mammalian ADP-ribosylation
complexity, and facilitating comparisons across any cellular
condition, cell type and, even, species. To substantiate this, we
have applied our established method to HeLa cells exposed to
hydrogen peroxide (H2O2)-induced oxidative stress (Fig. 1a), and
to normal mouse liver samples. Second, using the Af1521 macro
domain to enrich ADP-ribosylated peptides, which has favourable
binding preferences and relatively high ADP-ribose afﬁnity with a
Kd ofB0.13 mM (ref. 26), allowed unbiased modiﬁed amino acid
analysis. Third, we have ensured prevention of lysis-induced
ADP-ribosylation artefacts, as previously reported20, thus
facilitating assessment of the ADP-ribosylome during actual
physiological conditions.
Identiﬁcation of the H2O2-induced ADP-ribosylome. To
benchmark our methodology, we treated HeLa cells with 500mM
H2O2, which induces PAR formation through oxidative stress
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Figure 1 | Proteome-wide identiﬁcation of endogenous ADP-ribosylation sites in human cell culture. (a) Schematic representation of the peptide-based
enrichment strategy. HeLa cells were treated with genotoxic stress and digested into peptides. Tryptic digested peptides were treated with PARG enzyme to
convert multimeric ADP-ribosylation into monomeric counterparts, and subsequently ADP-ribosylated peptides were enriched using GST-Af1521
macrodomain. Enriched peptides were analysed by high-resolution LC-MS/MS on an Orbitrap Q-Exactive HF instrument and the data was further
processed by bioinformatic software tools. (b) Comparison of HeLa cells exposed with 500mM H2O2. During cellular knock-down of PARG enzyme
(siPARG) an abundant PAR signal is observed, while under physiological conditions the PAR signal is signiﬁcantly weaker (compare second lane with fourth
lane on gel). Previous methods for characterizing ADP-ribosylation solely worked under siPARG conditions while the methodology described here
is applicable to physiological conditions. (c) Optimization of the incubation time and amount of PARG enzyme required for converting multimeric
ADP-ribosylated peptides into monomeric counterparts. (d) Validation experiment that conﬁrms PARG treatment does not remove MAR from investigated
peptides. (e) Venn diagram of identiﬁed ADP-ribosylation sites identiﬁed in two biological replicate analyses. A strong overlap in identiﬁed sites
signiﬁes high reproducibility in the developed method. (f) GO functional annotation of signiﬁcantly regulated proteins in the combined data set
reveal strong enrichment of proteins involved in DNA repair processes compared with annotated GO genes across the entire human genome (indicated
P-valueso0.005). (g) GO term annotation enrichment for cellular distribution of proteins harbouring ADP-ribosylation sites.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12917 ARTICLE
NATURE COMMUNICATIONS | 7:12917 | DOI: 10.1038/ncomms12917 | www.nature.com/naturecommunications 3
signalling. Under physiological conditions (non-siPARG
conditions), H2O2 treatment induces PAR levels only faintly
detectable by immunoblot (Fig. 1b), while cellular knock-down
of PARG via small interfering RNA (siPARG) causes strong
PAR formation (Fig. 1b). This demonstrates the requirement
for improved sensitivity in studying ADP-ribosylation under
unperturbed physiological conditions.
To ensure complete catalysis of PARylated into MARylated
peptides we next assessed the amount of PARG required to
catalyse a ﬁxed amount of PAR. Previously, PAR levels in HeLa
cells have been reported to range up to 0.1 amol per cell during
H2O2 treatment27. Thus, we incubated 10 mM of puriﬁed PAR
with increasing concentrations of PARG and assessed the
temporal efﬁciency of the catalysis by immune-slot blot
(Fig. 1c). Since the most efﬁcient catalysis was observed when
PAR was treated with PARG for 3 h, we concluded that this
enzyme ratio allowed enzymatic catalysis of PARylated peptides
into MARylated peptides during our enrichment procedure.
As some macrodomains can exhibit hydrolase activity on MAR
moieties28,29, we performed the Af1521 enrichment procedure at
4 C and incubated samples for only two hours. Moreover, all
subsequent sample handling steps were performed at 4 C, which
collectively prevents hydrolase activity of the Af1521 macro
domain20. To conﬁrm that PARG exerted no enzymatic hydrolase
activity on MAR (ref. 19) in our workﬂow, we assessed whether
PARG removes ADP-ribosylation from automodiﬁed ARTD1
(also PARP1) or ARTD10 (formerly PARP10; Fig. 1d), which are
known PARylated and MARylated substrates30, respectively.
Using autoradiography assays, hydrolysis of the attached
radioactive [32P]-PAR of the protein substrates was monitored
(Fig. 1d), revealing that PARG was indeed able to convert PAR
chains on ARTD1 into MAR, while no reaction was observed
regarding the auto-MARylation of ARTD10 (Fig. 1d). These
results conﬁrmed that PARG hydrolase activity would not affect
enrichment of MAR residues.
To evaluate the reproducibility of the methodology, we
performed replicate enrichment experiments in HeLa cells.
Following MS analysis, there was a 75% overlap of the high-
conﬁdent ADP-ribose acceptor sites identiﬁed (localization scores
40.60) between replicates (Fig. 1e). Thus, this indicates high
reproducibility in the established approach, which compares
well with the reproducibility obtained in other proteomic
experiments (Supplementary Note 1)31. From three replicates,
we have identiﬁed 739 ADP-ribosylation sites (Localization score
40.60) on 480 proteins after H2O2 treatment (Supplementary
Data 1), with the majority of identiﬁed proteins containing a
single modiﬁcation site (Supplementary Fig. 1b). To corroborate
our identiﬁcation analysis, we performed a separate MS analysis
employing the complementary fragmentation technique electron
transfer dissociation (ETD)32, which conﬁrmed the localization of
several identiﬁed sites (Supplementary Fig. 1c,d; Supplementary
Data 2).
Functional analysis using gene ontology (GO) conﬁrmed that
the identiﬁed proteins participate in biological processes known
to involve ADP-ribosylation activity, including transcription,
chromosome organization and response to DNA damage
stimulus33,34 (Fig. 1f). Reassuringly, we ﬁnd that 76% of the
ADP-ribosylated proteins localize to the nucleus (Fig. 1g), in line
with the cellular localization of ARTD1 and ARTD2 (also
PARP2). Moreover, the cellular abundance proﬁle of identiﬁed
ADP-ribosylation protein targets supports the notion that
our methodology is not biased towards abundant proteins
(Supplementary Fig. 1e). Collectively, these results conﬁrm the
feasibility and reproducibility of this novel proteomics approach
for identifying the endogenous ADP-ribosylation sites in cultured
HeLa cells.
Identiﬁcation of Lys residues as endogenous acceptor sites. As
the Af1521 macro domain binds to the ADP-ribose moiety26 our
methodology allows for unbiased detection of any ADP-ribose
acceptor site. In support of this, no discernable difference was
observed when the amino acid distribution of ADP-ribosylation
sites was compared with the amino acid distribution of the
same residues across the proteome (Fig. 2a). Among the
identiﬁed ADP-ribosylation sites, we observed a signiﬁcant
portion of modiﬁcations residing on Lys residues, including the
previously conﬁrmed ARTD1 modiﬁcation site K498 (ref. 7).
ADP-ribosylation of Lys residues has been suggested as an
artefact related to the release of ADP-ribose moieties during
PARG cleavage of PAR chains17. This suggestion was made based
on observations that ADP-ribose was found to non-enzymatically
attach to Lys, Arg and Cys residues in a glycation process35.
However, the incorporation rate (stoichiometry) achieved in this
study, which utilized large amounts of histone proteins for
in vitro reactions, were estimated to be below 2%, suggesting that
this is an inefﬁcient reaction35. To investigate whether PARG
treatment of PAR chains causes glycation in our experimental
setup, we performed a quantitative experiment using Stable
Isotope Labelling by Amino acids in Cell culture (SILAC)36.
Herein ‘Heavy’ SILAC cell lysates were treated with free PAR
chains before PARG degradation, while ‘Light’ SILAC cell lysates
were left untreated (Supplementary Fig. 2a). Since no
PAR-inducing stress was exerted on these cells, identiﬁcation of
ADP-ribosylation sites exhibiting increased SILAC ratios would
be indicative of chemical reactions caused by free ADP-ribose
released by PARG. Here we identiﬁed 39 ADP-ribosylation sites
equally distributed across Lys, Arg, Glu and Asp residues, and no
increased SILAC ratios were observed for identiﬁed modiﬁcation
sites. These ﬁndings strongly suggest that PARG treatment does
not lead to random glycation of Lys or Arg residues (Fig. 2b
and Supplementary Data 3). To substantiate our ﬁndings, we
performed a ‘reverse’ SILAC experiment where only light SILAC
cells were treated with free PAR chains, which resulted in a
similar outcome (Fig. 2b). These results conﬁrm that ADP-ribose
moieties released on PARG treatment are unlikely to cause
relevant in vitro artefacts and, combined with the overall
reproducibility of ADP-ribosylation site identiﬁcation (Fig. 1e),
suggest that the identiﬁed ADP-ribosylation sites were not
derived from non-enzymatic glycation.
In addition, an in vitro experiment utilizing a synthesized
histone H2B-like peptide (NH2-PQPAKSAPAPKKG-OH) incu-
bated with free ADP-ribose was performed analogous to
previously reported experiments35. Brieﬂy, the non-modiﬁed
H2B peptide was incubated with 1mM ADP-ribose at 37 C at
pH 9 or 7.5 for two time points (1 h or overnight incubation).
Glycation levels were then determined using time-of-ﬂight (TOF)
MS (Supplementary Fig. 2b). On incubation with free
ADP-ribose, only small levels of glycation were observed,
dependent on pH and incubation time (Supplementary Fig. 2b).
Tandem mass spectrometry (MS/MS) conﬁrmed that glycation
took place at Lys residues (Supplementary Fig. 2c), corroborating
earlier observations that free ADP-ribose is able to modify Lys
residues by non-enzymatic glycation. However, our data reveal
that glycation occurs primarily at high pH and requires
non-physiological concentrations of free ADP-ribose. In
contrast, PARG-released ADP-ribose was not able to induce
similar artefacts at detectable levels. Moreover, the non-enzymatic
glycation of ADP-ribose occurred primarly on several Lys
residues within the short H2B-peptide, which is in stark
contrast to the different ADP-ribosylation sites observed in cell
culture (Supplementary Fig. 1b). Collectively, these results
strongly suggest that the ADP-ribosylation sites observed in our
cell culture analysis were not caused by glycation.
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To further validate Lys residue ADP-ribosylation in vivo, we
biochemically conﬁrmed the Lys modiﬁcation sites identiﬁed on
FEN1, CEBPB and SSRP1 in cells using an in vitro PARylation
assay. To this end, recombinant proteins for these target
substrates were puriﬁed as wild type (WT) and potentially
modiﬁcation-deﬁcient mutant variants, with the latter harbouring
K-to-A mutations at Lys residues that we found to be modiﬁed
(K354A for FEN1, K133A for CEBPB and K640A for SSRP1)
(Supplementary Data 1). All proteins were incubated with
puriﬁed ARTD1 in the presence of [32P]-NADþ and a DNA
fragment to measure the incorporation of NADþ radioactivity by
autoradiography37. Activation of ARTD1 was conﬁrmed by a
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Figure 2 | Lysine residues are in vivo targets of ADP-ribosylation in human cells. (a) Distribution of ADP-ribosylation acceptor sites compared with their
distribution in the genome. (b) Assessment of peptide glycation by free ADP-ribose. Distribution of log2 transformed SILAC ratios, and ADP-ribosylation
acceptor sites, from forward and reverse SILAC experiments as outlined in Supplementary Fig. 2a. No increased SILAC ratios were observed for the
different acceptor sites when cells were treated with PAR, supporting the notion, that the observed modiﬁcations are not derived from glycation.
(c) In vitro PARylation of identiﬁed protein targets. Puriﬁed full-length human ARTD1 was incubated with recombinantly expressed proteins in the presence
of 32P-NADþ and double-stranded DNA oligomer. Samples were resolved by SDS–PAGE, stained with Coomassie (CB; lower panel) and 32P-incorporation
was detected by autoradiography (P32; upper panel). (d) HeLa cells stably expressing SRSF1, SRSF2 CBX4 or TAF15 as GFP-fusion proteins were
treated with H2O2 and PARP (that is, ADP-ribosylation) inhibitor olaparib as control experiment. Lysates were subjected to Af1521 WT pull-down
or GFP-immunoprecipitation and subsequently analysed by immunoblotting with GFP antibody. Error bars are 95% conﬁdence intervals with n¼4.
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strong automodiﬁcation (Fig. 2c, upper panel). Using ARTD1
we detected strong ADP-ribosylation signals for all three WT
protein candidates, conﬁrming that these are ADP-ribosylation
substrates. When Fen1, CEBPB or SSRP1 were trans-modiﬁed
with either ARTD1, ARTD1þ PJ34, ARTD1 Y907A/C908R
(catalytically dead) or ARTD1 E988K (1.25% of wild-type
activity; only monomers are added), modiﬁcation of the
substrates was not observed (Supplementary Fig. 3), conﬁrming
that glycation is not a problem in our in vitro assays.
However, in our data set we observed several other
ADP-ribosylation sites in this protein, although these had lower
localization scores. These ﬁndings suggest that the K640
modiﬁcation may only contribute a low percentage of the total
ADP-ribosylation levels for SSRP1. Conversely, for the K133A
mutant of CEBPB9, we observed a 16% decrease in the
ADP-ribosylation signal. Analogously, when K354 was mutated
to Ala in FEN1, a reduction in total PAR signal was also observed,
thus conﬁrming that this residue constitutes an ADP-ribosylation
site. Altogether, these ﬁndings demonstrate that Lys residues
are indeed speciﬁc targets of ADP-ribosylation. In addition,
we conﬁrmed SRSF1, SRSF2, TAF15 and CBX4 as in vivo
ADP-ribosylated protein substrates using western blot (WB)
analysis (Fig. 2d). These targets were selected for three reasons:
TAF15 is a known ADP-ribosylated substrate during oxidative
stress9,20 and serves to demonstrate the ability of the
methodology to conﬁrm known targets. For SRSF1, the
identiﬁed modiﬁcation sites were observed with localization
scores of 0.5, and therefore do not constitute bona ﬁde
high-conﬁdent sites (Supplementary Data 1). Importantly, we
demonstrate that the data obtained could still be used to infer that
SRSF1 is an ADP-ribosylation target substrate as WB conﬁrmed
the MS results. Finally, both SRSF2 and CBX4 are novel
ADP-ribosylation targets harbouring high-conﬁdent modiﬁcations
sites.
ADP-ribosylation and PAR formation dynamics correlate.
Since the established enrichment approach requires PARG
enzymatic conversion of ADP-ribosylated acceptor sites into their
MARylated counterparts, we examined the dynamics of the
H2O2-induced ADP-ribosylation sites identiﬁed using SILAC. For
this, Light SILAC cells were stimulated for only a few seconds
with 500mM H2O2 (B0min), while heavy SILAC cells were
treated with the same concentration of H2O2 for various
durations (0, 5, 10, 30, 60 and 120min) (Supplementary Fig. 4a).
Using this approach, we investigated the effect oxidative stress
(H2O2 treatment) has on the abundance of ADP-ribosylation sites
determined by quantitative MS: if the identiﬁed ADP-ribosylation
site is induced on oxidative stress, then the relative SILAC peptide
intensity ratio between light and heavy peaks will be higher in the
heavy isotope encoded sample, thereby exhibiting an increased
SILAC ratio. Following MS analysis of H2O2-treated SILAC
samples, we extracted and compared the temporal SILAC ratios
of identiﬁed ADP-ribosylation sites, and observed the highest
SILAC ratios at early time points (5 and 10min H2O2 treatment)
(Fig. 3a). To examine whether changes in SILAC ratios correlate
with the dynamics of cellular PAR formation, we compared the
SILAC readout signal (Fig. 3a) to the PAR signals analysed by
immunoﬂuorescence in the same cells. Although the employed
antibody primarily recognizes only longer PAR chains, the
employed approach constitutes a widely used methodology to
evaluate relative differences (that is, dynamic changes) in cellular
PAR formation38–40 (Fig. 3b; Supplementary Fig. 4b). From
triplicate IF experiments a good temporal and kinetic correlation
between the measured SILAC ratios (Fig. 3a) and PAR IF signals
was observed (Fig. 3b), with both analyses exhibiting the highest
increase at 5–10min of H2O2 treatment. Moreover, the
dynamic changes observed are similar to results obtained from
immuno-slot-blot analysis of PAR formation (Supplementary
Fig. 4c), and to those reported in mouse embryonic ﬁbroblasts
treated with 100mM H2O2. Also in these experiments a peak of
PAR formation was observed after 5min, with subsequent
turnover after 15–20min (ref. 39). Collectively, these data show
that the upregulation of ADP-ribosylation sites determined by
SILAC ratios correlates with the increase in PAR formation using
IF analysis.
Determination of endogenous ADP-ribosylation stoichiometry.
Today, large-scale proteomics experiments have been very
successful in determining the relative abundance of PTMs
between different cellular states11. However, an inherent
challenge in PTM analyses is the estimation of stoichiometry,
referred to as the fraction of a given protein modiﬁed with a
particular PTM at a given amino acid. To obtain stoichiometry
information, we used the information gathered in our
H2O2-treated SILAC experiments (Fig. 3a and Supplementary
Data 1), and combined it with data characterizing general protein
regulation during H2O2 treatment41. Brieﬂy, ADP-ribosylated
peptides have opposite ratios of their unmodiﬁed counterparts,
which can be used to calculate the absolute stoichiometry of
modiﬁed sites from any two SILAC states. This calculation is
made under the assumption that the sum of modiﬁed and
unmodiﬁed peptides remains constant between SILAC states41.
From a single experiment, we obtained stoichiometry values
for 55 ADP-ribosylation sites, revealing that half of the
ADP-ribosylation sites have less than 11% stoichiometry on
H2O2 treatment (that is, the fraction of a given modiﬁcation site
occupied by ADP-ribosylation; Supplementary Fig. 4d). In line
with the overall transient nature of the modiﬁcation, these
ﬁndings suggest a tight enzymatic regulation of ADP-ribosylation
stoichiometry. Moreover, several of the arginine residue
ADP-ribosylation sites were measured with high stoichiometry
(Supplementary Fig. 4e, Supplementary Data 4). Whether these
represent protein targets modiﬁed by ARTs other than ARTD1
and 2, or represent MARylation rather than PARylation remains
to be determined.
Comparing this ADP-ribosylome to Asp/Glu ADP-ribosylomes.
With the wide range of ADP-ribosylated proteins identiﬁed,
we sought to compare our list of modiﬁed proteins with the
previously reported proteins ADP-ribosylated at Asp/Glu (ref. 9).
Although these analyses were conducted in different cell lines and
under different physiological conditions, we found that 36 per
cent of the reported Asp/Glu ADP-ribosylated proteins were also
modiﬁed in our data set (Fig. 3c). Similarly, 38% of the targets
identiﬁed in our previous report using the Af1521 domain for
identiﬁcation of ADP-ribosylated proteins20 were also identiﬁed
with the current methodology (Supplementary Fig. 4f).
This overlap increased to 52 percent when only H2O2-induced
ADP-ribosylation substrates were compared, supporting the
notion that differences in the substrates identiﬁed do not stem
from the methodologies but from differences in cellular
conditions (Supplementary Fig. 4f). Similarly, when comparing
our data set with an in vitro analysis where 8-Bu(3-yne)T-NADþ
was incubated with cell lysates and mutated analogue-sensitive
ARTDs42 an overlap of only 30% was observed (Fig. 3d). These
ﬁndings suggest that in vivo and in vitro strategies target different
ARTD substrates.
To further investigate the comparability of the different
enrichment strategies, we performed SILAC experiments in
which the PARP inhibitor olaparib was introduced before
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Figure 3 | SILAC ratios of ADP-ribosylation sites. (a) Boxplot analysis of logarithmized H/L SILAC ratios from six SILAC experiments representing HeLa
cells treated with H2O2 in a temporal manner (see Supplementary Fig. 2a). Strongest regulation of ADP-ribosylation sites is observed when cells are treated
for 5–10min of genotoxic stress. (b) Densiometric evaluation of IF analysis of HeLa cells treated with H2O2 for different time points. The strongest
abundance in PAR signal is observed after 5–10min treatment of H2O2, in good correlation with observed increase in SILAC ratios on MS analysis (Fig. 2a).
Experiments were performed in triplicates. (c) Venn diagram depicts overlap between identiﬁed ADP-ribosylated proteins compared with previously
reported Asp and Glu ADP-ribosylated proteins. (d) Venn diagram depicts overlap between identiﬁed ADP-ribosylated proteins compared with previously
reported Asp and Glu ADP-ribosylated proteins using an in vitro strategy. (e) Comparison of identiﬁed ARTD1 ADP-ribosylation sites across different
experiments as indicated. (f) Multi-scatter plot of measured peptide signal intensities from triplicate ADP-ribosylation experiments. A strong Pearson
correlation signiﬁes high reproducibility in the measured abundance of ADP-ribosylated peptide species. (g) Abundance measurement for seven
ADP-ribosylation sites, demonstrating that lysine residue K498 is abundantly modiﬁed in ARTD1. Error bars are 95% conﬁdence intervals with n¼ 3.
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oxidative stress and compared the outcome with the analogous
ADP-ribosylome experiment9. In two SILAC experiments, both
light and heavy SILAC cells were treated with H2O2, while only
light SILAC cells were treated with olaparib (1 mM or 10mM)43.
A strong Pearson correlation in SILAC ratios between the
experiments (R¼ 0.69) signiﬁes that the ADP-ribosylation sites
identiﬁed were similarly affected by the employed olaparib
concentrations (Supplementary Fig. 4g). Using the STRING
database of physical and functional interactions44, we found that
the proteins harbouring ADP-ribosylation sites regulated by
olaparib were strongly connected with ARTD1 and ARTD2
(Supplementary Fig. 5a). Moreover, the regulated proteins were
also strongly associated with biological processes known to
involve ARTDs (Supplementary Fig. 5b) and therefore most
probably constitute ADP-ribosylated candidates.
Next, we compared the protein distribution of identiﬁed
modiﬁcation sites between this data set and the above-mentioned
methodology. In the Asp/Glu ADP-ribosylome9, a total of 1,048
ADP-ribosylation sites residing on 320 proteins were identiﬁed,
which corresponds to 3.3 modiﬁcations per identiﬁed substrate.
In contrast, our combined data set includes 958 ADP-ribosylation
sites on 565 proteins, or 1.7 modiﬁcations per identiﬁed substrate.
Considering that only half of the identiﬁed sites in our data set
reside on Glu or Asp residues (Fig. 2a), the boronic acid
approach, which employs non-physiological siPARG conditions,
identiﬁes more ADP-ribosylation sites per identiﬁed substrate.
Notably, this increase is analogous to the observed increase in
overall PAR signal on siPARG treatment (Fig. 1b).
We then compared the ADP-ribosylation sites only identiﬁed
on ARTD1. In the Asp/Glu ADP-ribosylome analysis by Zhang
et al.9, a total of 37 ADP-ribosylation sites were reported for
ARTD1 (Fig. 3e), of which 23 resided on Glu residues, which
corresponds to 31% of the total number of Glu within human
ARTD1. In contrast, the Af1521 analysis only identiﬁed
ADP-ribosylation in a total of 11 amino acid acceptor sites
across all experiments (Fig. 3e). To investigate whether the
differences in the number of identiﬁed ADP-ribosylation sites
might be abundance-driven, we performed an analysis of HeLa
lysates without Af1521 enrichment. In addition, we performed a
similar analysis with recombinant ARTD1, where automodiﬁed
ARTD1 was treated with PARG but not enriched by Af1521.
From these experiments, we solely found K498 to be modiﬁed in
the non-enriched HeLa sample, whereas both K498 and K505
were identiﬁed on recombinant ARTD1 (Fig. 3e). These data
suggest that certain Lys residues within the auto-modiﬁcation
domain of ARTD1 are most abundantly present in the analysed
samples, which is similar to previous mutational observations
for ARTD1 (ref. 7). We observed a strong reduction in the
in vitro PAR signal when the three lysine residues within the
automodiﬁcation domain of ARTD1 (K498R, K521R and K524R)7
were mutated. Thus, indicating that these sites are indeed relevant
for automodiﬁcation of ARTD1 and supporting our observations
that K498 is a major PAR acceptor site of ARTD1.
To quantify ARTD1 modiﬁcation sites in more detail, we next
compared the peptide signal abundance between replicate Af1521
analyses (Fig. 1e). To this end, the intensity values for all
identiﬁed peptide sequences were compared across replicate
samples. A strong Pearson correlation between replicates
(R40.89) demonstrates that the measured peptide signal
intensities can be used as a reliable measure for modiﬁcation
site abundance (Fig. 3f). To further investigate quantiﬁcation of
ADP-ribosylation sites, we performed abundance assessment for
seven modiﬁcation sites on ARTD1 that were reliably identiﬁed in
two out of the three replicate experiments (Fig. 3g). The analysis
revealed that ADP-ribosylation located on lysine K498 yielded the
strongest signal abundance. Although peptides from the same
protein might exhibit different ‘ﬂyability’45, an observed 34-fold
and 420-fold difference in signal intensity compared with nearby
modiﬁcation sites residing on glutamic acids E520 and E488,
respectively, suggests that K498 is an abundant auto-modiﬁcation
site on ARTD1. Besides, ADP-ribosylation on K498, both E488
and E491 reside on comparable tryptic peptide sequences within
ARTD1, so that the observed differences in abundance cannot
be attributed to different peptide ionization propensities. We
observed that quantiﬁed ADP-ribosylation sites preferentially
reside within the auto-modiﬁcation domain of ARTD1 under
physiological conditions (Fig. 3g,e).
Analysing endogenous ADP-ribosylation sites in mouse liver.
Tissues can contain many different cell types that display a wide
range of protein concentrations, which poses challenges to pro-
teomic identiﬁcation and the analysis of PTMs. Moreover, many
tissues contain a broad range of different mono-ARTs, including
members of the ARTD family, SIRTs and ARTCs (ref. 46). To
further explore the general applicability of the new method,
we characterized the endogenous ADP-ribosylome of mouse liver,
a tissue that has already been described to regulate cellular
processes in an ADP-ribosylation-dependent manner47. Three
C57BL/6 mice were killed before their livers were collected and
frozen in liquid nitrogen. The tissue was then ground up and
processed as described for the HeLa cells (Fig. 4a). In triplicate
analyses, we identiﬁed 901 modiﬁed peptides with unique
ADP-ribosylation acceptor sites, of which 414 were identiﬁed in
at least two different liver samples (Fig. 4b, Supplementary
Data 5). The distribution of ADP-ribosylation sites was similar to
the cell culture analysis, with 70% of identiﬁed proteins
harbouring only one modiﬁcation site (Fig. 4c). Strikingly, the
majority (86%) of identiﬁed ADP-ribosylation acceptor sites in
the mouse liver were Arg, while Lys, Asp and Glu were detected
only at very low levels compared with HeLa cells (Fig. 4d).
Notably, several Lys residues modiﬁed with ADP-ribosylation
were also found on cytoplasmic proteins in this analysis
(Supplementary Data 5), providing evidence that lysine residues
being in vivo targets of ADP-ribosylation under physiological
conditions.
GO analysis of the modiﬁed proteins revealed a high
enrichment in mitochondrial, cytoplasmic, nuclear and mem-
brane proteins (Fig. 4e). Among the identiﬁed ADP-ribosylated
proteins, we found several previously reported ADP-ribosylated
proteins. These included ARTD12 (formerly PARP12), which has
been described to have MAR and auto-ADP-ribosylation activity;
ARTC2, which is a GPI-anchored arginine-speciﬁc MARylating
enzyme that can be shed and circulated in the blood; and
glutamate dehydrogenase 1, which is known to be regulated
through ADP-ribosylation by SIRT4 (refs 48,49). In agreement
with experiments done in HeLa cells, we also found that
histone H2B and several RNA helicases were modiﬁed. These
results indicate that the established enrichment protocol
can readily be employed to investigate the non-induced
ADP-ribosylomes of tissues, which include both intra- and
extra-cellular ADP-ribosylated proteins.
Discussion
Here, we describe the establishment of a robust and highly
reproducible technology for the ﬁrst unbiased proteome-wide
view of a mammalian ADP-ribosylome, which includes the exact
identiﬁcation of endogenous ADP-ribose acceptor sites under
different physiological conditions in cells and for the ﬁrst time
also in organ tissue. We show that PARG treatment of peptides
before enrichment with Af1521, allows speciﬁc identiﬁcation of
ADP-ribosylated amino acids and highly sensitive identiﬁcation
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of the corresponding proteins. And we demonstrate that the
detected modiﬁcations are not derived from non-enzymatic
glycation and, contrary to previous claims50, Af1521 does not
hydrolyse the modiﬁcation under the applied conditions. Besides,
this method supports the identiﬁcation of ADP-ribosylated
proteins without complementing cell lysates or organelles
with NADþ analogues and mutated ARTDs (ref. 18) and is,
consequently, able to analyse the ADP-ribosylome under different
cellular conditions derived from endogenous ARTD protein and
NADþ levels in both cells and tissue.
The streamlined methodology led to the identiﬁcation of more
than 900 endogenous ADP-ribosylation sites belonging to more
than 500 proteins in both culture and tissue cells. Our results
suggest that this methodology could be used in combination with
high-throughput screening techniques to identify endogenous
proteins affected by ADP-ribosylation and/or those modulated
by ADP-ribosylation inhibitors (also called PARP inhibitors).
ARTD1 is a key regulator within the DDR (ref. 33), which has
recently become a highly attractive target for cancer therapy51,52.
Although not speciﬁc for ARTD1, several ADP-ribosylation
inhibitors have been approved or are currently being evaluated in
clinical trials as mono-therapeutic or combination therapy agents.
Our ability to now analyse the endogenous ADP-ribosylome from
different cancer cells or tissues constitutes a promising approach
that should advance of our understanding of ADP-ribosylation in
a clinical setting.
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FEN1 is a structure-speciﬁc nuclease with 50-ﬂap endonuclease
and 50–30 exonuclease activities involved in DNA replication
and repair, and ARTD1 recruits FEN1 to DNA damage
intermediates53. The K354 reside of FEN1 becomes acetylated
through the acetyltransferase p300, which reduces the
DNA-binding activity of FEN1 (ref. 54), while ubiquitylation of
the same lysine mediates the proteosomal degradation of FEN1
during G2/M phase55. These PTM-based regulatory mechanisms
support the notion that ADP-ribosylation at K354 might relate to
a currently uncharacterized regulatory function of FEN1.
The observed ADP-ribosylation of the SUMO-protein ligase
CBX4 suggests nuclear cross-talk between PARylation and
SUMOylation, which might be more widely occurring than
previously anticipated. Such cross-talk could be analogous to
previously reported ADP-ribosylation-dependent ubiquitylation
(PARdu)56. In fact, CBX4 is known to mediate SUMO
conjugation in the DDR, and the recruitment of CBX4 to sites
of DNA lesions is dependent on ADP-ribosylation57. Thus,
our observation that CBX4 becomes ADP-ribosylated during
oxidative stress strongly suggests that we have identiﬁed a
previously uncharacterized DDR regulatory mechanism
controlled by PARylation-dependent SUMOylation (PARsu).
The presented methodology is suitable for the identiﬁcation of
key endogenous ADP-ribosylation events in biological processes.
We ﬁnd that ADP-ribosylated proteins are on average less
modiﬁed under physiological conditions than reported under
siPARG treatment9, which suggests that deregulation of PARG
alters physiological ADP-ribosylation homoeostasis (Fig. 1b)13,39.
Moreover, our MS analysis supports that Lys residues K498 and
K505 are major acceptor sites in ARTD1, which follows previous
mutational analysis of ADP-ribosylation sites on ARTD1 (ref. 7).
Our analysis indicates that under physiological conditions
ARTD1 is activated in cis58, contradicting the observed in trans
activation of ARTD1 under siPARG treatment9.
Comparison of the SILAC and IF data obtained from HeLa
cells revealed that the dynamic changes induced by H2O2 for
these two data sets correlate well with each other. The relative
increase in peptide abundance may thus suggest that the
ADP-ribosylation sites detected reﬂect PARylation, at least
partially. However, since the methodology described here
cannot discriminate between MAR and PAR, each regulated
ADP-ribosylation site will require follow-up experiments to
determine whether they are indeed PARylated or MARylated.
The importance of tissue-speciﬁc protein ADP-ribosylation
mapping is underscored by the substantial differences in
ADP-ribosylation observed between cell culture and tissue (that
is, liver). In mouse liver tissue the majority of ADP-ribosylated
proteins localize to compartments containing enzymes with MAR
activity, such as ARTD10, ARTD8, ARTC and SIRT4, suggesting
that these proteins are primarily MARylated rather than
PARylated (Fig. 4e). These observations are further supported
by the increased levels of modiﬁed Arg residues, and membrane
and extracellular proteins, which might stem from ARTC activity.
Moreover, our data substantiates initial studies where
ADP-ribosylation was observed on Arg residues within rat liver
proteins59. From the analysed liver extracts, ARTD1 was not
found to be auto-ADP-ribosylated, highlighting the fact that the
enzyme is mainly inactive under normal, non-stressed conditions.
Our organ analysis of ADP-ribosylation provides evidence that
the modiﬁcation is involved in multiple physiological functions.
For example, KEGG pathway analysis reveals that proteins
involved in actin cytoskeleton and endoplasmic reticulum
regulation are enriched in ADP-ribosylation (Supplementary
Fig. 5c). These pathways have previously been associated with
ADP-ribosylation60,61, but the mechanism by which the
modiﬁcations are catalysed (that is, ARTDs or ARTCs (ref. 62))
remains to be investigated. NADþ can be released on necrosis or
mechanic stress in tissue, which in turn likely activates ARTCs
during organ collecting63. Considering that ARTCs have higher
afﬁnity for NADþ compared with ARTD1, this renders ARTCs
more prone to activation following NADþ release during tissue
collecting. Moreover, we ﬁnd that proteins involved in metabolic
processes, oxidative-reduction processes and mitochondrial
content are distinctly enriched in ADP-ribosylation targets
(Fig. 4e and Supplementary Fig. 5f), which suggests these
processes may be inﬂuenced by the modiﬁcation. While the
exact mechanisms are not well understood, inhibition of ARTDs
is known to enhance these processes64. With ARTD1 activation
known to affect cellular metabolism via direct PARylation events,
transcriptional reprogramming, or alterations in cellular NADþ
levels64, our tissue analysis supports the hypothesis that metabolic
consequences on ADP-ribosylation inhibition might occur via
alterations in NADþ levels65. This is based on ARTD1 being an
avid NADþ consumer, and that ADP-ribosylation inhibition
increases the cellular levels of NADþ available for other
ARTDs (ref. 65), in a manner reminiscent of the reported
interplay between ARTD1 activity and deacetylase SIRT1
(ref. 66). Furthermore, with immortalized cell lines exhibiting
mitochondria and metabolic processes deﬁciencies67, hereby
rendering them impractical for ADP-ribosylation inhibition/
activation and cellular metabolism investigations, highlights
that methodologies allowing proteomics-based whole tissue
analyses are required to investigate this antagonistic interplay in
more detail.
In conclusion, our novel methodology allows for the unbiased
and sensitive characterization of ADP-ribosylation sites under
physiological conditions, while the data presented here
extends current ADP-ribosylation knowledge and highlights the
widespread occurrence of the modiﬁcation. Although the
methodology presented cannot currently distinguish between
MARylated and PARylated peptide species, adjustment of the
binding reaction stringency and combining the enrichment
with speciﬁc MAR-binding domains, will most likely facilitate
dissecting peptide MAR- versus PARylation in a more speciﬁc
manner68. Importantly, the approach presented supports
comprehensive and quantitative evaluation of the mammalian
ADP-ribosylome of cell lines and tissue samples. Thus, allowing
downstream interrogation of disease pathways in which ARTs are
implicated.
Methods
Cell culture and transfection. HeLa cells were grown in Dulbecco’s modiﬁed
Eagle’s medium (D-MEM; Invitrogen) supplemented with 10% foetal bovine serum
and penicillin/streptomycin (100Uml 1) (Gibco). Stable HeLa-Kyoto cells
expressing CBX4, SRSF2, SRSF1 and FUS tagged with C-terminal GFP under the
control of an endogenous promoter were generated by transfecting BAC transgenes
and were kindly provided by Prof Anthony Hyman (Max Planck Institute, Dres-
den). Selection was maintained by adding 400 mgml 1 G418 (Sigma Aldrich) to
the culture medium. SILAC HeLa cells were grown in SILAC D-MEM (Invitrogen)
supplemented with 10% dialyzed foetal bovine serum, L-glutamine, penicillin/
streptomycin, and either L-lysine and L-arginine, L-lysine 4,4,5,5-D4 and
L-arginine-U-13C6, or L-lysine-U-13C6-15N2 and L-arginine-U-13C6-15N4
(Cambridge Isotope Laboratories)36. The siRNA oligonucleotides against
endogenous PARG (ID: 4390826) was purchased from Ambion as well as Negative
Control siRNA#1. SiRNA transfections were performed using Lipofectamine
RNAiMAX (Invitrogen) according to the manufacturer’s protocol and lysed 48 h
after transfection. All HeLa cells used for experiments were tested negative for
mycoplasma.
Sample preparation. Cells were stimulated with H2O2 (Sigma Aldrich) for 10min
in PBS at 37 C, collected by washing with ice-cold PBS and lysed in modiﬁed RIPA
buffer (50mM Tris pH 7.5, 400mM NaCl, 1mM EDTA, 1% Nonidet P-40, 0.1%
Na-deoxycholate), protease inhibitor mixture (Roche) supplemented with 2mM
Na-orthovanadate, 5mM NaF, 5mM Glycero-2-phosphate, 1 mM ADP-HPD
(Millipore) and 40mM PJ-34 (Enzo Life Sciences) and cleared by high-speed
centrifugation. Proteins were precipitated by adding fourfold excess volumes of
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ice-cold acetone and stored at  20 C overnight. Subsequently, proteins were
solubilized in a urea solution (6M urea/2M thiourea/10mM HEPES pH 8.0).
Protein concentrations in lysates were measured using Bradford assay (Bio-Rad).
Next, proteins were reduced by adding dithiothreitol to a ﬁnal concentration of
1mM, and alkylated with chloroacetamide at 5.5mM. Proteins were digested using
endoproteinase Lys-C (1:100 w/w) and modiﬁed sequencing grade trypsin (1:100
w/w) after a fourfold dilution in 50mM ammonium bicarbonate solution. Protease
digestion was terminated by slow addition of triﬂuoroacetic acid to pH 2.
Precipitates were removed by centrifugation for 10min at 3,000g. Peptides were
puriﬁed using reversed-phase Sep-Pak C18 cartridges (Waters). Peptides were
eluted off the Sep-Pak with 50 and 80% acetonitrile.
GST-protein expression and puriﬁcation of Af1521. BL21 was used for long
transformation. Brieﬂy, 1 ml of cooled plasmid was added to BL21 and left on ice
for 15min. Bacteria were heat shocked at 42 C for 45 sec, incubated for 1min on
ice and then mixed with SOC for 40min at 37 C. Bacteria were streaked onto
Amp-plates and left overnight at 37 C. The following day a single colony was
inoculated in LB media and grown overnight at 37 C. The starter culture was
diluted and grown to an OD600 of 0.55–0.65. Protein expression was induced by
adding IPTG to ﬁnal concentration of 0.5mM and incubated for 5–6 h. Bacteria
were spun down and pellet frozen at  80 C.
The bacterial pellet was thawn and incubated for 20min in lysis buffer (50mM
Tris–HCl, pH 7.5, 150mM NaCl, 1mM MgCl2, 1mM dithiothreitol, 1Bug
Buster (Novagen), 1 ml ml 1 Benzonase (Sigma Aldrich), 200mgml 1 lysozyme
(Sigma Aldrich), protease inhibitor mixture (Roche)). After breaking cells by
vortexing with glass beads, cell debris was pelleted by centrifugation. The cleared
lysate was incubated for 4 h at 4 C rolling with equilibrated glutathione sepharose
4B (Sigma Aldrich). Beads were washed four times in wash buffer (50mM
Tris–HCl, pH 7.5, 150mM NaCl and 1mM dithiothreitol), resuspended in wash
buffer and kept at 4 C for up to 3 weeks.
Enrichment of ADP-ribosylated peptides. After eluting off Sep-Pak, appropriate
amounts of IP buffer (50mM Tris–HCl, pH 8, 10mM MgCl2, 250 mM
dithiothreitol and 50mM NaCl) was added before the acetonitrile and the volume
was reduced by vacuum centrifugation. PAR complexity was reduced by incubation
with PARG (4.2 mg per sample) for 3 h at 37 C. The peptide mixture was cooled
down before it was incubated rotating for 2 h at 4 C with the puriﬁed Af1521
macro domain. The peptides were washed three times in ice-cold IP buffer followed
by one wash in water, and modiﬁed peptides were eluted with 2 100 ml 0.15%
TFA in Milli-Q water. Peptide eluates were desalted on reverse phase C18
StageTips69.
Mass spectrometric analysis. All MS experiments were performed on a
nanoscale EASY-nLC 1000 UHPLC system (Thermo Fisher Scientiﬁc) connected
to an Orbitrap Q-Exactive Exactive equipped with a nanoelectrospray source
(Thermo Fisher Scientiﬁc). Each sample was eluted off the StageTip, auto-sampled
and separated on a 15 cm analytical column (75 mm inner diameter) in-house
packed with 1.9-mm C18 beads (Reprosil Pur-AQ, Dr Maisch) using a 3 h
gradient ranging from 5 to 64% acetonitrile in 0.5% formic acid at a ﬂow rate of
200 nlmin 1. The efﬂuent from the high-performance liquid chromatography was
directly electrosprayed into the mass spectrometer. The Q Exactive Plus mass
spectrometer was operated using data-dependent acquisition, with all samples
being analysed using a ‘sensitive’ acquisition method22 and a normalized
collision energy of 28. Back-bone fragmentation of eluting peptide species were
obtained using HCD which ensured high-mass accuracy on both precursor and
fragment ions.
Mass spectrometry analysis of ADP-ribosylation sites by ETD. ETD spectra of
ADP-ribosylated peptides were acquired on an Orbitrap Fusion Lumos mass
spectrometer (Thermo Scientiﬁc) operating in positive ion mode. Full MS scans
(m/z 300–1,500) were performed at 120,000 resolution (m/z 200) in the Orbitrap,
with the AGC target set at 4e5. Precursor selection was prioritized on the basis of
highest charge state followed by highest intensity. Peptides (charge states from 3þ
to 6þ ) were selected by the quadrupole (1.3 m/z isolation window) before reaction
with ﬂuoranthene radical anions (ETD reagent target 4e5). ETD reaction times
were set at 1.7t for each charge state. MS/MS spectra were acquired using a normal
ion trap scan rate with a maximum injection time of 50ms (AGC target 2e5).
A Venn diagram comparing identiﬁed protein targets derived from the ETD with
HCD analysis is shown in Supplementary Fig. 6a.
In vitro TOF-MS analysis of H2B peptide sequence. 1 mg of HK326 peptide
(PQPAKSAPAPKKG) was incubated with 1mM ADP-ribose in 50mM sodium
phosphate buffer (pH 7.5 and pH 9.5) for 1 h or overnight at 37 C. Samples were
desalted using Reversed-phase m-C18 ZipTips (for MALDI-MS) and eluted
with MALDI matrix solution (a-cyano-4-hydroxycinnamicacid in 0.3mM
di-ammonium hydrogen citrate (Fluka), 60% acetonitrile in H2O) directly on the
target plate. MALDI analyses were performed on a 4800 MALDI TOF/TOF system
in linear mode.
Identiﬁcation of peptides and proteins. All raw data analysis was performed
with MaxQuant software suite version 1.3.0.5 supported by the Andromeda
search engine70. Data were searched against a concatenated target/decoy
(forward and reversed) version of the UniProt Human fasta database encompassing
71,434 protein entries (downloaded from www.uniprot.org on 2013-07-03).
Mass tolerance for searches was set to maximum 7 p.p.m. for peptide masses
and 20 p.p.m. for HCD fragment ion masses. Data were searched with
carbamidomethylation as a ﬁxed modiﬁcation and protein N-terminal acetylation,
methionine oxidation and mono-ADP-ribosylation (m/z 541,06110:
C10H13N5O9P2) on lysine, arginine, glutamic and aspartic acids as variable
modiﬁcations. A maximum of three mis-cleavages was allowed while requiring
strict trypsin speciﬁcity, and only peptides with a minimum sequence length of
seven were considered for further data analysis. Peptide assignments were
statistically evaluated in a Bayesian model on the basis of sequence length and
Andromeda score. Only peptides and proteins with a false discovery rate of o1%
were accepted, estimated on the basis of the number of accepted reverse hits, and
false discovery rate values were ﬁnally estimated separately for modiﬁed and
unmodiﬁed peptides. Protein sequences of common contaminants such as human
keratins and proteases used were added to the database. For SILAC quantiﬁcation a
minimum of two ratio-counts was required.
Enrichment of GFP-tagged and ADP-ribosylated proteins. Cells expressing the
tagged versions of the proteins of interest were collected by washing with PBS and
lysed in modiﬁed RIPA buffer (50mM Tris pH 7.5, 400mM NaCl, 1mM EDTA,
1% Nonidet P-40, 0.1% Na-deoxycholate), protease inhibitor mixture (Roche)
supplemented with 2mM Na-orthovanadate, 5mM NaF, 5mM Glycero-2-
phosphate, 1 mM ADP-HPD (Millipore) and 40 mM PJ-34 (Enzo Life Sciences).
Lysates were diluted in modiﬁed RIPA without salt and then cleared by high-speed
centrifugation.
GFP-immunoprecipitaion was performed with 20 ml GFP-Trap_A agarose
beads (Chromotek). 1mg of protein mixtures were incubated for 2 h rotating at
4 C before washing and subsequent elution with 2 Laemmli sample buffer
(Thermo Fisher Scientiﬁc) at 90 C. Pull down of ADP-ribosylated proteins was
performed similarly but using 200 ml crosslinked Af1521 macro domain and 2mg
of protein mixtures.
Western blotting. The following antibodies were used in this study: rabbit
polyclonal PAR 1:1,000 (ALX-210–890A, Enzo Life Science) and mouse
monoclonal GFP 1:1,000 (11814460001, Roche).
Total cell lysates together with the eluates were resolved on 4–12% gradient
SDS–PAGE gels (Thermo Fisher Scientiﬁc) and proteins were transferred onto
nitrocellulose membranes (Sigma Aldrich). Membranes were blocked using 5%
BSA solution in PBS supplemented with Tween-20 (0.1%). Secondary antibodies
coupled to horseradish peroxidase (Jackson ImmunoResearch Laboratories)
were used for immunodetection. The detection was performed with Novex ECL
Chemiluminescent Substrate Reagent Kit (Invitrogen). For slot blot analysis, PAR
polymer (Trevigen) was incubated with different concentrations of PARG and
spottet directly onto PVDF membranes (Millipore) using the slot blot chamber
(Fisher Scientiﬁc) according to manufacturer’s protocol. Cropped WBs presented
in Fig. 2d have been included as uncropped scans in Supplementary Fig. 6b.
Immunoﬂuorescence microscopy. HeLa cells were seeded on coverslips and the
following day stimulated for indicated time points with H2O2. After washing with
PBS, cells were ﬁxed in methanol/acetic acid solution and incubated for 5min at
37 C. Coverslips were blocked in 5% milk powder, transferred to a humid chamber
and incubated with rabbit polyclonal PAR (Enzo Life Science) for 1 h at 37 C and
with secondary antibody Alexa Fluor 488 (Invitrogen) for 1 h at 37 C, stained with
DAPI for 2min, washed in PBS and mounted. Images were acquired on a DFC345
FX microscope (Leica) and analysed using ImageJ.
Immuno-slot-blot. For the immuno-slot-blot analysis, HeLa cells were treated and
lysed as described in sample preparation, and proteins were vacuum aspirated onto
a Hybond P 0.2 PVDF (Amersham Biosciences) using a slot-blot manifold
(Amersham Biosciences). The membrane was blocked with 5% milk powder in
10mM Tris–HCL (pH 8.0), 150mM NaCl and 0.05% (v/v) Tween 20 (TBST
buffer) and incubated with polyclonal PAR antibody (Enzo Life Science) diluted
1:1,000 in 5% milk powder in TBST for 1 h at RT and with secondary antibody
IRDye 800CW goat anti-rabbit IgG (LI-COR) 1:15,000 in TBST for 1 h at RT.
Signals were detected by the Odyssey infrared imaging system (LI-COR) and the
immunoblot signal was quantiﬁed using GelEval (FrogDance Software).
In vitro radiography assay. 10 pmol of ARTD1 and ARTD10 were automodiﬁed
with 100 nM NADþ for 10min at 37 C, respectively, hereby inducing short PAR
chains on ARTD1 and MAR on ARTD10 through auto-catalysis29. Samples were
ﬁltered through G50 columns to remove excess amount of unincorporated NADþ ,
and subsequently treated with 10 pmol PARG for additional 1 h at 37 C. Using
autoradiography assays the hydrolysis of attached radioactive 32 P-NADþ of the
protein substrates were subsequently monitored. For transmodiﬁcation reactions,
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50 pmol of target protein was incubated with 10 pmol ARTD1 for 10min at 37 C.
The reaction was stopped by adding Laemmli buffer and boiling for 5min at 95 C.
After separation of samples by SDS–PAGE, the radiolabelled ADP-ribosylation
signal was determined by GelEval (FrogDance Software).
Preparation of mouse liver extracts. Male 9-week-old C57BL/6 mice were
maintained on a 12-h light–dark cycle with regular unrestricted diet. Mice were
killed in a CO2 chamber. Excised livers were washed in PBS and shock frozen in
liquid nitrogen. Ice-cold modiﬁed RIPA buffer (supplemented with PARP-, PARG-
and protease inhibitors as described before) was added to the shock frozen livers
and they were lysed operating the Tissue Lyser II (Qiagen) device at 30HZ for
4 30 s. The lysate was further sonicated until it became ﬂuid and all liver pieces
were dissolved. The lysate was cleared by high-speed centrifugation and processed
similar as described for the cell culture samples. 20mg of liver protein was used as
starting material for the digest.
Bioinformatic analyses. Statistical analysis and hierarchical clustering was
performed using the Perseus software suite (Max Planck Institute of Biochemistry,
Department of Proteomics and Signal Transduction, Munich). Signiﬁcantly
enriched Gene Ontology terms were determined using the Functional Annotation
Tool of the DAVID Bioinformatics database. Protein interaction networks were
analysed using the interaction data from the STRING database (v. 9.05) and
visualized using Cytoscape (v. 2.8.3). Protein abundance assessment was performed
using a deep proteome reference data set for HeLa cells. All Venn diagrams were
generated using the online Venny program (http://bioinfogp.cnb.csic.es/tools/
venny/).
Comments related to animal study. C57BL/6J mice were bread at the animal
facility of the University of Zurich. No randomization or blinding were used for
these studies, and no animals had to be excluded. All animal experiments were
carried out in accordance with the Swiss and EU ethical guidelines and have been
approved by the local animal experimentation committee of the Canton of Zurich
under licence #2012207 and following the 3R guidelines.
Data availability. The mass spectrometry proteomics data have been deposited to
the ProteomeXchange Consortium via the PRIDE partner repository71 with the
data set identiﬁer PXD004245. The additional data that support the ﬁndings of this
study are available from the corresponding author on request.
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